Streetbeat News

Stock Prices

EIS

SPY

USO

Hezbollah has reportedly fired on North Israel, according to Reuters citing two security sources. The news may have implications for the iShares MSCI Israel ETF (EIS), SPDR S&P 500 ETF Trust (SPY), and United States Oil Fund LP (USO).

Portfolio Pulse from Benzinga Newsdesk

October 09, 2023 | 6:34 pm

MDB

MongoDB (NASDAQ:MDB) has outperformed the market over the past 5 years by 31.56% on an annualized basis, producing an average annual return of 40.94%. If an investor had bought $100 of MDB stock 5 years ago, it would be worth $570.22 today.

Portfolio Pulse from Benzinga Insights

October 09, 2023 | 6:30 pm

WM

Waste Management's (NYSE:WM) short percent of float has fallen 8.18% since its last report, with 4.09 million shares sold short, which is 1.01% of all regular shares available for trading. This decrease in short interest could indicate a more bullish market sentiment towards the stock. Compared to its peers, Waste Management has less short interest as a percentage of float, with an average of 2.72%.

Portfolio Pulse from Benzinga Insights

October 09, 2023 | 6:30 pm

SYY

Sysco's (NYSE:SYY) short percent of float has fallen 14.81% since its last report, with 6.98 million shares sold short, which is 1.38% of all regular shares available for trading. This decrease in short interest could signal a more bullish market sentiment towards Sysco. Compared to its peers, Sysco has less short interest as a percentage of float, with an average of 3.75%.

Portfolio Pulse from Benzinga Insights

October 09, 2023 | 6:30 pm

KDP

Keurig Dr Pepper's (NYSE:KDP) short percent of float has fallen 10.85% since its last report, with 10.90 million shares sold short, which is 1.15% of all regular shares available for trading. This decrease in short interest could signal a more bullish market sentiment towards the stock. Compared to its peers, Keurig Dr Pepper has less short interest.

Portfolio Pulse from Benzinga Insights

October 09, 2023 | 6:30 pm

CLDI

Baird has initiated coverage on Calidi Biotherapeutics Inc (NYSE:CLDI) with an Outperform rating and a price target of $9. The company, which uses allogeneic stem cells to deliver oncolytic viruses to tumors for cancer treatment, recently went public via a SPAC. Early clinical data of its lead agent CLD-101 showed promising results in glioma patients. However, the company is operating with a brief cash runway of approximately 12 months, which is exerting downward pressure on the stock.

Portfolio Pulse from Vandana Singh

October 09, 2023 | 6:21 pm

AXON

Axon Enterprise, Inc. (NASDAQ:AXON) shares rose after the Federal Trade Commission (FTC) dismissed its antitrust complaint against the company. The complaint was related to Axon's 2018 acquisition of competitor Vievu. The FTC's dismissal will result in a global resolution of both cases, ending a 5-year battle to protect Axon's intellectual property and investors.

Portfolio Pulse from Ryan Gustafson

October 09, 2023 | 6:21 pm

DIS

Needham analyst Laura Martin has reiterated a Hold rating on Walt Disney Co (NYSE:DIS) and lowered her Q4 2023 estimates for the company. The revision is due to lower expectations for Content Sales, Parks and Experiences, and Linear Networks, partially offset by higher revenue in the DTC segment. Martin's new estimates include a 4Q revenue of $21.4 billion, operating income of $2.8 billion, and adjusted EPS of $0.76. The analyst also projects FY23 revenue of $89.09 billion, FY24 revenue of $93.52 billion, and FY25 revenue of $97.76 billion.

Portfolio Pulse from Anusuya Lahiri

October 09, 2023 | 6:19 pm

ABBV

A significant investor has taken a bearish stance on AbbVie (NYSE:ABBV), with 54% of the investors opening trades with bearish expectations. The whales have been targeting a price range from $75.0 to $160.0 for AbbVie over the last 3 months. The current price of ABBV is down -0.52% at $147.47. Raymond James has downgraded its action to Outperform with a price target of $177.

Portfolio Pulse from Benzinga Insights

October 09, 2023 | 6:16 pm

IMAX

IMAX Corp's 3Q global box office earnings significantly exceeded analyst Mike Hickey's estimate, generating $347 million. The earnings achieved 141% of its pre-pandemic performance for the same quarter, indicating a strong recovery. Hickey maintained a Buy rating for IMAX and raised the price target from $23 to $24. However, IMAX shares traded lower by 2.14% at $19.40 on the last check.

Portfolio Pulse from Anusuya Lahiri

October 09, 2023 | 6:13 pm